Arcturus Therapeutics Holdings Inc. announced on November 16, 2026, that it entered into a Securities Purchase Agreement with Meiji Seika Pharma Co., Ltd. Under the agreement, Arcturus sold 2,466,395 shares of its common stock to Meiji for a total purchase price of $50.0 million. The shares were sold at a price of $20.27 per share, which represents an 80% premium over the average closing price of Arcturus' common stock over the 30 trading days ending November 11, 2026.
The transaction closed concurrently with the signing of the agreement. As a result of the sale, Meiji beneficially owns approximately 7.9% of Arcturus' outstanding shares. The investment is not registered under the Securities Act and was conducted pursuant to Section 4(a)(2) of the Act.
Arcturus and Meiji also executed a registration rights agreement, requiring the company to file a registration statement on Form S-3 to allow Meiji to resell the shares. The registration must be filed no later than 180 days after the closing and declared effective within 90 days of filing, subject to specific SEC review timelines. Additionally, the agreement includes a refund provision: if a definitive license agreement is not entered into by May 31, 2027, Arcturus must refund Meiji 50% of the premium paid, or approximately $11.1 million.
Concurrently with the equity transaction, Arcturus and Meiji entered into an exclusive license agreement regarding the application of ARCT-154 technology for an undisclosed therapeutic area. Meiji will be responsible for the development and commercialization costs for this program. Furthermore, the parties signed a non-binding memorandum of understanding (MOU) outlining terms for a potential exclusive license of Arcturus' self-amplifying mRNA and lipid nanoparticle technologies for pandemic preparedness and response in Japan. Neither party is currently obligated to enter into the definitive agreement outlined in the MOU.